Who
Evan Lippman
EVP, Business Development
Company insider
Files Form 4 as: EVP, Business Development, Teva Pharmaceutical Industries.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $4.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 May 2025
- Last trade
- 17 Aug 2026
- Last filed
- 19 Aug 2026
Companies traded
Activity over time
1 May – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Aug 2026filed 19 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $680K18,600 at $36.57 | filing |
| 17 Aug 2026filed 19 Aug 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $680K18,600 at $36.57 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —11,841 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $204K5,746 at $35.58 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —74,008 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,841 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —74,008 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $1.3M35,912 at $35.58 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —11,841 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —74,008 at $0.00 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —11,841 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $204K5,746 at $35.58 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Code M | —74,008 | filing |
| 14 May 2026filed 18 May 2026 | TEVA Teva Pharmaceutical IndustriesPharmaceuticals | SEC FORM 4 Sold | $1.3M35,912 at $35.58 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —27,347 at $0.00 | filing |
| 4 Mar 2026filed 6 Mar 2026 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —27,347 at $0.00 | filing |
| 14 May 2025filed 19 May 2025 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —47,365 at $0.00 | filing |
| 14 May 2025filed 19 May 2025 | TEVA Teva Pharmaceutical Industriesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —148,016 at $0.00 | filing |
News
Comparing Harrow (NASDAQ:HROW) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 16 Oct 2026Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $50.00TEVA · dailypolitical.com · 15 Oct 2026Analyzing Astrazeneca (NYSE:AZN) & Teva Pharmaceutical Industries (NYSE:TEVA)TEVA · tickerreport.com · 13 Oct 2026
0 headlines in the last 90 days name Evan Lippman; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.